Shilpa Medicare Ltd


1W Return


1M Return


6M Return


1Y Return


3Y Return


Start SIP in Shilpa Medicare Ltd
Stock Performance
52 Week Low - High
Today’s Low - High


Prev. Close

Total Traded Value

View details of Market Depth

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
New 52W High in past week
TTM PE Ratio
Negative PE TTM
Price to Book Ratio
Below industry Median
Dividend yield 1yr %
PEG TTM is much higher than 1
RSI Overbought
MFI strongly Overbought

Shilpa Medicare Ltd Key Financials

*All values are in ₹ Cr.

Shilpa Medicare Ltd shareholding Pattern

Foreign Institutions
Mutual Funds
Domestic Institutions

Shilpa Medicare Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
Bearish Moving Averages
5Day EMA
10Day EMA
12Day EMA
20Day EMA
26Day EMA
50Day EMA
100Day EMA
200Day EMA
Delivery & Volume
Resistance & Support
First Resistance
Second Resistance
Third Resistance
First Support
Second support
Third Support
Relative Strength Index
Money Flow Index
MACD Signal
Average True Range
Average Directional Index
Rate of Change (21)
Rate of Change (125)

Shilpa Medicare Ltd Company background

Founded in: 1987
Managing director: Vishnukant Bhutada
Shilpa Medicare Limited (formerly known as Shilpa Antibiotics Limited) was incorporated as a Private Limited Company in November 20th, 1987 and has been promoted by Vishnukant C Bhutada and his associates. Shilpa Medicare Limited (SML) is engaged in manufacturing of Active Pharmaceutical Ingredients (API), Formulation and Development service. The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka. The company started commercial production in November 1989. In November 1993, Shilpa Medicare Limited was converted into a Public Limited Company. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology. It supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. While SMLs underlying expertise is in the field of oncology, it also derives revenue from sale of nononcology APIs. With key products being Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India.SMLs product range includes over 44 oncology and nononcology APIs. The Companys formulation product range consists of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SMLs wholly owned subsidiary Shilpa Therapeutics Private Limited.SML deals in highquality Active Pharmaceutical Ingredients (APIs), Bulk drug, Intermediates, Formulations and Development service, New Drug Delivery Systems, Peptides / Biotech products and Specialty Chemicals etc. using sophisticated technology meticulously in order to comply with laid down international standards/specifications. SML is among the worlds leading suppliers of Oncology/NonOncology APIs and intermediates.In year 1992, the company installed production facilities to manufacture sodium methoxide. During FY 2015, projects of five products transfer executed successfully, other projects of eight products have been completed and ready for transfer to plant. Ten new molecules have been taken for development considering future demand.During FY15, as part of mobilization of resources for the purpose of expanding the operations of the Company, fresh funds were raised by allotting 17,64,705 equity shares of Rs.2/ each to Tano Mauritius India FVCI II, the existing member of the Company, at a premium of Rs 423/each on 15 May 2014 on preferential basis.During FY2016, the company after obtaining the approval of members at the 28th Annual General Meeting held on 28 September, 2015, divided the face value of existing equity share of Rs.2/ into two equity shares of Re.1/ each fully paidup, with effect from the Record Date specified. Raichem Medicare Pvt Ltd., a subsidiary of Shilpa Medicare, completed installation of all machineries during the FY 20152016 and recruited all the key personnel, also commenced trial production in August 2015 after the Audit by External Consultant from Italy and started commercial production in December2015. The subsidiary obtained the Drug Manufacturing license and GMP certificate and consent from pollution control board for operating the plant. In FY 1617, Shilpa Medicare launched the generic versions of Vidaza Injection Xeloda Tablets. During the year under review, as part of mobilization of resources for the purpose of expanding the operations of the company, fresh funds were raised by allotting 30,25,000 equity shares of Re.1/ each to TA FII Investors Limited, at a premium of Rs.569/ each on 26 December, 2016 on preferential basis.Pursuant to the order dated 24 November 2017 of Honble National Company Law Tribunal, Bangalore Bench, the Navya Biologicals Private Limited has been merged with the Company with effect from 1 April 2016 being the appointed date for merger.During the year 2019, an amount of Rs 22.71 crore was invested into its wholly owned subsidiary, Shilpa Therapeutics Pvt Ltd. (STPL) by way Loan to meet the project cost which is being setup at Cherlapally, Telangana.During the year 2019, the Company disinvested 24% of stake in Raichem Medicare Private Limited, erstwhile Joint venture, and sold to Joint Venture Partner ICE S.p.A.In FY 2019, the company incorporated Shilpa Pharma Inc. as a wholly owned subsidiary in United States of America. During the current FY 201920, the Company formed Sravathi Advance Process Technologies Private Limited to foray into the RD activities of specific drug processes by roping prominent technocrats. It launched the Indian branded generic of Ibrutinib, an anticancer drug under the brand name IBRUSHIL. During the financial year 20192020, Shilpa launched Azacitidine, covering the majority of European countries. It launched the first Indian Branded Generic of Lenvatinib Mesylate under the brand name Lenshil which is used for the treatment of differentiated thyroid cancer (DTC) and hepatocellular carcinoma. It sold 26% stake and exited from in Raichem Medicare Private Limited, erstwhile Joint Venture, in the month of June, 2020. It incorporated Shilpa Albumin Private Limited and Shilpa Biologicals Private Limited as Wholly Owned Subsidiaries of the Company.In 2021, the Company launched a pediatric dose paracetamol oral thin film, under the brand name Molshil in strengths of 60 mg and 120 mg. It commissioned the State of Art Centralized Finished Dosages RD Centre at Dabaspet near Bangalore. In 2021, Shilpa Biologicals Pvt Ltd, (SBPL), a wholly owned subsidiary of Company signed an agreement with Dr. Reddys Laboratories for productionsupply of Sputnik V vaccine from its integrated Biologics RD cum manufacturing center at Dharwad, Karnataka. It formed Sravathi AI Technology Private Limited, Shilpa Corporate Holdings Private Limited and Koanna Helathcare, Cananda. In FY22 the Company received an approval from the Defence Research Development Organization (DRDO) for the manufacture and sale of 2DeoxyDGlucose (2DG). It commissioned a combo line for ODF/TDS.During the year 202122, Shilpa Corporate holdings Private Limited an investment company, has been formed as a wholly ownedsubsidiary, which acquired 100% stake in FTF Pharma Private Limited an an integrated drug development company, Koanaa Healthcare Canada, Koanaa International FZ LLC (Dubai), Indo Biotech SDN. BHD Malaysia, and so that all these companies have become as wholly Owned Subsidiaries. Further, the Company acquired balance 25% equity shares of INM Technologies Private Limited and made a wholly owned subsidiary. INM Technologies Private Limited which is the wholly owned subsidiary of the Company holds 25% of its stake in INM Nuvent Paints Private Limited. The Company had disposed off the total stake in Loba Feinchemie Gmbh, a step down subsidiary in Austria. In year 2022, the Company launched 12 formulations in India. The new launches were in the therapeutic areas of oncology, nononcology, and products for the OTC market such as women hygiene, vitamin supplements and an antioxidant green tea film. It commissioned new RD center for polymer peptide, created separate wing for CDM0 with its scientific head.In 2022, the Shareholders of the Company have approved the Slump sale of Active Pharmaceutical Ingredient (API) Business of theCompany consisting of Unit1 and Unit2 situated at Raichur, Karnataka to its wholly owned subsidiary Shilpa Pharma Lifesciences Limited. The Company, has duly executed the Business Transfer agreement with Shilpa Pharma Lifesciences Limited (Formerly known as Shilpa Corporate Holdings Private Limited) which is complete and effective from 30 June 2022.
Read More

Shilpa Medicare Ltd FAQs

Shilpa Medicare Ltd shares are currently priced at 437.2 on NSE and 437.35 on BSE as of 2/22/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Shilpa Medicare Ltd [SHILPAMED] share was 56.36. The Shilpa Medicare Ltd [SHILPAMED] share hit a 1-year low of Rs. 222.6 and a 1-year high of Rs. 454.8.

The market cap of Shilpa Medicare Ltd is Rs. 3794.98 Cr. as of 2/22/2024 12:00:00 AM.

The PE ratios of Shilpa Medicare Ltd is 0 as of 2/22/2024 12:00:00 AM.

The PB ratios of Shilpa Medicare Ltd is 1.78 as of 2/22/2024 12:00:00 AM

The Mutual Fund Shareholding was 0.06% at the end of 2/22/2024 12:00:00 AM.

You can easily buy Shilpa Medicare Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
or Resume your Application
+91 -